Physician profile
Bruce W Bode
NPI 1841297751
$1,533,148.06
in general payments reported to CMS, 2019-2025
84 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $386K · 2020: $275K · 2021: $299K · 2022: $246K · 2023: $216K · 2024: $97K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188K · Consulting Fee: $83K · Travel and Lodging: $37K · Food and Beverage: $19K · Honoraria: $500 · Education: $60.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $187,947.44 |
| Consulting Fee | $82,728.48 |
| Travel and Lodging | $37,036.49 |
| Food and Beverage | $19,018.23 |
| Honoraria | $500.00 |
| Education | $60.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $327,083.55 | 2019-2025 | Mounjaro, Lyumjev, Jardiance |
| Novo Nordisk INC | $320,165.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $208,294.49 | 2019-2025 | |
| Mannkind Corporation | $90,277.07 | 2019-2025 | Afrezza, V-Go |
| Xeris Pharmaceuticals, INC. | $89,526.92 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Senseonics, Incorporated | $76,416.00 | 2019-2025 | Eversense |
| Medtronic, INC. | $65,369.38 | 2019-2024 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Novo Nordisk As | $50,715.88 | 2020-2023 | |
| Medtronic Minimed, INC. | $41,130.62 | 2019-2020 | |
| Companion Medical, INC. | $40,488.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $29,154.35 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26,033.28 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $25,799.55 | 2019-2020 | |
| Abbott Laboratories | $23,204.41 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Eli Lilly and Company | $18,514.32 | 2019-2024 |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $15,821.27 | 2021-2025 | Cequr Simplicity |
| Astrazeneca Uk Limited | $10,988.09 | 2019 | |
| Tandem Diabetes Care, INC. | $9,797.95 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $9,338.00 | 2019-2025 | Omnipod |
| Ascensia Diabetes Care US INC. | $9,146.04 | 2021-2024 | |
| Zealand Pharma US, INC. | $8,890.65 | 2020-2022 | |
| Pfizer INC. | $7,607.59 | 2019 | |
| Sequel Med Tech, LLC | $6,492.02 | 2025 | Twiist |
| Zealand Pharma A/S | $3,750.00 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $3,498.82 | 2019-2020 | |
| Beta Bionics, INC. | $2,197.39 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $1,592.21 | 2020-2025 | |
| Intuity Medical INC | $1,318.91 | 2022 | |
| Amgen INC. | $1,285.99 | 2019-2025 | Tepezza, Repatha, Evenity |
| Vertex Pharmaceuticals Incorporated | $1,170.00 | 2025 | |
| Corcept Therapeutics | $1,040.42 | 2019-2025 | Korlym |
| Bigfoot Biomedical INC | $725.66 | 2022-2023 | Unity Diabetes Management System |
| Dexcom, INC. | $701.44 | 2019-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $623.81 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $518.03 | 2019-2025 | Unithroid |
| Abbvie INC. | $433.12 | 2019-2024 | Ubrelvy |
| Amarin Pharma, INC. | $418.19 | 2019-2022 | |
| Ibsa Pharma INC. | $344.81 | 2019-2024 | Tirosint, Licart, Licart |
| Radius Health, INC. | $322.38 | 2021-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $254.39 | 2020-2023 | Januvia, Steglatro, Belsomra |
| Valeritas, INC. | $240.66 | 2019 | |
| Becton, Dickinson and Company | $194.56 | 2019-2022 | |
| Averitas Pharma INC. | $178.40 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $156.97 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $140.07 | 2019-2023 | Aveed, Xiaflex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.39 | 2019-2024 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $128.21 | 2020-2024 | Nexletol |
| Madrigal Pharmaceuticals | $126.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Alexion Pharmaceuticals, INC. | $122.35 | 2019-2024 | Strensiq |
| Clarus Therapeutics INC. | $92.19 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $90.03 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $87.48 | 2021-2025 | Isturisa, Signifor Lar |
| Kvk-Tech, INC. | $80.23 | 2019 | |
| Embecta Corp. | $79.98 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Horizon Therapeutics Plc | $76.80 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $63.14 | 2024-2025 | Yorvipath, Skytrofa |
| Nalpropion Pharmaceuticals LLC | $52.17 | 2019 | |
| Janssen Scientific Affairs, LLC | $47.06 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $45.14 | 2024-2025 | |
| Eisai INC. | $44.59 | 2023 | |
| Currax Pharmaceuticals LLC | $43.67 | 2020 | |
| Genentech USA, INC. | $43.30 | 2023 | Vabysmo |
| Lifescan, INC. | $41.52 | 2019-2020 | |
| Chiesi USA, INC. | $40.03 | 2024-2025 | Myalept |
| Nevro Corp. | $37.85 | 2021-2024 | Senza |
| Tolmar, INC. | $31.43 | 2025 | Jatenzo |
| Acerus Pharmaceuticals Corporation | $30.39 | 2022 | |
| Astellas Pharma US INC | $29.66 | 2024 | Veozah |
| Smith+Nephew, INC. | $22.38 | 2019-2020 | |
| Soleno Therapeutics, INC. | $21.50 | 2025 | Vykat Xr |
| Verity Pharmaceuticals INC. | $20.68 | 2024 | Tlando |
| Nestle Healthcare Nutrition INC. | $20.35 | 2021 | |
| Alvogen INC | $20.02 | 2024 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $19.98 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.95 | 2020 | |
| Kyowa Kirin, INC. | $18.89 | 2025 | |
| Shire North American Group INC | $18.39 | 2019 | |
| Vivus LLC | $14.87 | 2021 | |
| Amryt Pharma Holdings Ltd | $13.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.39 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$163,154.81 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Bode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.